{"id":"19854335-2daf-4802-af1c-b9216787c300","arxiv_id":"2508.09373","paper_version":1,"verdict":"REJECT","confidence":"LOW","novelty_score":3.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":2,"one_line_summary":"High B7-H3 expression in initial prostate biopsy samples is associated with shorter survival and more aggressive disease in men with advanced prostate cancer.","lead":"A retrospective study of 248 men with prostate cancer found that tumors with high levels of the immune protein B7-H3 in initial biopsies were tied to worse survival and more aggressive disease. The paper suggests this protein, measured at diagnosis, could help identify high-risk patients and may become a target for new therapies.","discovery_kind":"replication","skeptic_critique":{"model":"deepseek-v4-flash","headline":"Central claim is not assessable: multivariable B7-H3 effect reported only as 'HR > 2' without CI, and the analysis-set size shifts between 248 and 135 (Table 1, Fig. 4).","rationale":"The reader's stated weakest assumption is the 50% cutoff. I agree that is unvalidated, but the more load-bearing problem is that the primary effect estimate is reported only as 'HR > 2' with no confidence interval, and the denominator of the survival analysis is unclear (248 in abstract/intro vs 135 in Table 1 and Fig. 4). If the actual analysis set is 135 metastatic patients with 41 high expressors, the multivariable result may be fragile; if it is 248, Table 1 and the missingness figure are inconsistent. Either way, the central claim 'potent and independent' is unverifiable from the paper. This overlaps with the reader's rationale (which lists the missing CI and denominator), but it is a different primary weak point than the cutoff, hence partial agreement. I keep the REJECT verdict because the reporting defects and unresolved confounders preclude acceptance, but the paper could in principle be salvaged by supplying the missing estimates, a flow diagram, and external validation.","tokens_in":14609,"tokens_out":6488,"duration_ms":69965,"concrete_test":"Request the full statistical output for the primary multivariable OS and DSS models on a fixed analysis set, including exact n, number of events, B7-H3 coefficient, HR, 95% CI, and p, together with a CONSORT-style flow diagram reconciling 248 with 135. Then reconstruct approximate HRs from the reported 5-year survival percentages (OS: 40% vs 62%; DSS: 64% vs 86%) using standard KM-based methods and form a CI; if the CI crosses 1.0, or the OS HR is not robustly above 2, the 'potent and independent' claim fails.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The paper's conclusion that B7-H3 is a 'potent and independent' prognostic biomarker in metastatic prostate cancer depends on a multivariable hazard ratio that is never actually reported. Section 3 states only that 'high B7-H3 remained a strong predictor of mortality, with a hazard ratio greater than 2' and gives a likelihood-ratio P<0.05; no point estimate, 95% confidence interval, or event count is provided for OS or DSS. This is not a cosmetic omission: with 94 low vs 41 high expressors in Table 1 (which totals 135) and the missing-data figure explicitly 'among 135 patients', while the Abstract/Introduction claim 248 men (135 metastatic, 113 localized), the survival model may be fit on a much smaller and less balanced cohort than the headline suggests. A 4-5 covariate model on 135 patients, with only 41 high expressors and unknown deaths, can produce unstable estimates; subgroup analyses by age and chemotherapy subdivide that group further. The manuscript itself flags residual confounding from unavailable comorbidity/lifestyle data and says it 'cannot entirely exclude' unmeasured confounders, and it concedes that optimal B7-H3 cutoffs need validation. Without the exact HR/CI and a reconciled patient flow, the central claim cannot be evaluated, let alone 'established.'","agreement_with_reader":"partial"},"referee_report":{"model":"deepseek-v4-flash","summary":"The paper retrospectively evaluates membranous CD276/B7-H3 expression by immunohistochemistry in diagnostic prostate biopsies from 248 men, including 135 with metastatic and 113 with localized disease. The authors report that high B7-H3 expression (≥50% moderate-strong membranous staining) is associated with higher PSA, more aggressive tumor features, and shorter overall and disease-specific survival. Survival analyses use Kaplan–Meier, log-rank, and Weibull/Cox multivariable models adjusted for age, PSA, Gleason grade, and metastatic spread. The paper claims that high B7-H3 remains a strong independent predictor of mortality with a hazard ratio 'greater than 2' and concludes that B7-H3 is a potent independent prognostic biomarker and potential therapeutic target in metastatic prostate cancer.","tokens_in":14850,"tokens_out":3907,"duration_ms":43203,"significance":"If the reported association is valid and reproducible, this study would address a genuine clinical gap: a biopsy-based prognostic marker applicable at diagnosis in advanced prostate cancer, with potential value for risk stratification and enrichment of trials of B7-H3-targeted therapies. The study has notable strengths: treatment-naïve baseline biopsies, independent blinded pathology review, multiple imputation for missing data, and combined nonparametric and parametric survival modeling. However, because the central multivariable effect is not reported with a point estimate, confidence interval, or event counts, and because the analysis cohort is ambiguously defined, the contribution cannot currently be evaluated. The clinical significance is real but contingent on transparent reporting and external validation.","major_comments":[{"comment":"The central claim of an 'independent' prognostic effect rests on a single sentence: 'high B7-H3 remained a strong predictor of mortality, with a hazard ratio greater than 2.' No point estimate, 95% confidence interval, exact p-value, event count, or regression table is provided for overall or disease-specific survival. This is not a stylistic omission; it makes the magnitude and precision of the adjusted effect impossible to assess. Please report full multivariable regression output (coefficient, SE, HR, CI, p-value) for OS and DSS, specify whether the 'greater than 2' result is from a Cox or Weibull model, and give the number of events in each B7-H3 group.","section":"Section 3, quantitative results"},{"comment":"The sample size is not reconciled. The Abstract and Introduction state 248 men (135 metastatic, 113 localized), but Table 1 reports 135 total patients (94 low, 41 high) and Figure 4 is captioned 'among 135 patients.' If all survival analyses are restricted to the metastatic subgroup of 135, this must be stated explicitly, and the patient flow from 248 to 135 must be documented. The absence of this reconciliation obscures the statistical power and balance of the survival model, especially with only 41 high expressors and unknown numbers of deaths. Please also report the number of events and median follow-up for each B7-H3 stratum.","section":"Table 1 and Figure 4"},{"comment":"The 50% positivity threshold for defining high versus low B7-H3 is stated without justification, and the Introduction itself acknowledges that 'no consensus exists for defining high versus low B7-H3 expression.' The paper neither optimizes this cutoff nor validates it in an external cohort. Because the entire survival association is conditional on this binary split, a sensitivity analysis using alternative thresholds or a continuous staining score is essential. Without it, the reported HR 'greater than 2' may be threshold-dependent. The age (<70 vs ≥70) and chemotherapy subgroup splits also appear arbitrary and should be justified or treated as hypothesis-generating.","section":"Section 2.1, B7-H3 cutoff"},{"comment":"Section 2.1 states that the study 'received formal approval from our Institutional Review Board' with a waiver of informed consent, but the Declarations section states 'Not applicable' for ethics approval and consent. These statements are mutually contradictory. The ethics reporting must be corrected, and the relevant IRB approval number or institutional policy should be provided. This is a procedural issue that also undermines reader confidence in the reported data provenance.","section":"Declarations vs. Section 2.1"},{"comment":"The Conclusion states that the study 'establishes' B7-H3 as an independent prognostic biomarker, yet the Discussion acknowledges residual confounding from unmeasured comorbidities, lifestyle factors, and functional status, and states that 'we cannot entirely exclude the possibility that unmeasured confounders may have influenced the observed relationships.' Given the limited multivariable adjustment (four covariates), the absence of external validation, and the arbitrary cutoff, the strong causal language is not supported. Either temper the conclusion or provide additional evidence such as an E-value for unmeasured confounding or validation in an independent cohort.","section":"Section 4, Discussion"}],"minor_comments":[{"comment":"The sentence 'Schoenfeld residuals were (see figure 1) and formally tested' is incomplete. Please rephrase and describe how the residuals were used to assess proportional hazards.","section":"Section 2.2"},{"comment":"Figure captions are incomplete. Please add axis labels, units, and legends. In particular, Figure 4(a) refers to '20 simulated PSA values missing among 135 patients'—clarify whether these are observed missing values or imputed simulations.","section":"Figures 1–4"},{"comment":"The p-values are reported without stating the statistical test used for each row. Please specify the tests (e.g., Wilcoxon rank-sum for continuous, Fisher exact/chi-square for categorical) and report exact p-values rather than rounded cutoffs where possible.","section":"Table 1"},{"comment":"The text alternates between 'Weibull regression' and 'Cox models' without making clear which model generated the hazard ratio 'greater than 2.' Please clarify the model used for each reported result.","section":"Section 3"},{"comment":"The paper states that formal inter-observer agreement statistics were not calculated, but '100% consensus was achieved following discussion.' Given that two pathologists independently scored all samples, reporting Cohen's kappa or at least the distribution of initial disagreements would strengthen the reproducibility claim.","section":"Section 2.1"},{"comment":"The reference list contains numerous self-citations to arXiv preprints and works in unrelated fields (e.g., soccer, turtle color patterns, pandemic control) that are cited as methodological support. These do not appear to substantiate the statistical or clinical choices in this paper. Please replace them with relevant methodological and clinical literature.","section":"References"},{"comment":"The statement 'Data sets were obtained from institutional records' is not a data availability statement. Please clarify whether de-identified data can be shared and under what conditions.","section":"Data availability"}],"recommendation":"major_revision","confidential_remarks":"The manuscript's central claim is potentially important, but the current reporting prevents a sound assessment. The authors should be asked to provide the exact multivariable effect estimates and confidence intervals, reconcile the 248 vs 135 sample sizes, justify or perform sensitivity analyses for the 50% cutoff, and correct the ethics declaration. I also noted a striking citation pattern: a large fraction of references are self-citations to unrelated arXiv preprints and papers on soccer, turtles, and pandemic control, while the actual B7-H3 literature is relatively compact. This does not affect my technical assessment, but it is worth the editor's attention for fit and scholarly attribution."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"The one genuinely new thing here is a separate cohort from Amori et al., with localized cases added and some exploratory age/chemotherapy subgroups. The authors follow the earlier protocol closely, use two blinded pathologists, apply multiple imputation, and run sensitivity checks. They also state their limitations plainly. That is real effort, and the paper has a legitimate question: does baseline biopsy B7-H3 predict survival in metastatic prostate cancer? The answer they get may be right, but the paper does not let you check it.\n\nThe central problem is that the multivariable effect is reported only as “hair ratio greater than 2” with a likelihood-ratio p<0.05. No point estimate, no confidence interval, no event count. That is not a cosmetic omission; it makes the main claim unassessable. The sample size inconsistency compounds it: the abstract says 248 men, but Table 1 sums to 135 and the missing-data figure explicitly says 135. If the survival model runs on the 135 metastatic patients only, that should be stated consistently, with a proper patient flow. The 50% cutoff is imported from prior work, no validation or alternative cutpoint analysis is given, and the ethics statement is self-contradictory: a detailed IRB approval in Section 2.1, then “Not applicable” in the Declarations. The heavy self-citation in unrelated fields is a distraction, and there is no data or code, but those are lesser issues relative to the missing estimate.\n\nIf the underlying data are real, a referee could reasonably ask for the full regression table, the reconciled denominator, a sensitivity analysis across cutpoints, and a corrected ethics statement. That would make the paper assessable. As it stands, the paper’s own conclusion that B7-H3 is an “independent” biomarker is not supported by the evidence presented. The reader’s REJECT is proportionate for the current version, but I would not desk-reject this outright because the clinical question is timely, the design follows a credible predecessor, and the flaws are fixable with revision.","headline":"A replicative B7-H3 prognostic study that cannot be evaluated as written because the key hazard ratio is never actually reported.","tokens_in":15394,"tokens_out":1560,"would_cite":false,"duration_ms":18075,"reading_group":"maybe","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"Tumor B7-H3 measured in the baseline biopsy predicts shorter survival in metastatic prostate cancer.","keywords":["prostate cancer","CD276/B7-H3","prognostic biomarker","diagnostic biopsy","immunohistochemistry","metastatic prostate cancer","survival analysis","immune checkpoint"],"falsifier":"Rescore the 135 metastatic biopsies with the percentage of stained tumor cells treated as a continuous variable or with cutpoints other than 50%, then test the chosen cutpoint in a separate treatment-naive metastatic cohort using the same antibody, scoring rules, and multivariable adjustment; the central claim fails if the hazard ratio for high versus low B7-H3 is no longer clearly above 1 or is not stable across plausible cutpoints.","tokens_in":14428,"feed_emoji":"🧬","tokens_out":9887,"duration_ms":96697,"temperature":0.7,"pith_summary":"The paper argues that measuring membranous CD276/B7-H3 in the diagnostic biopsy, before any treatment begins, can identify which men with prostate cancer are already on a high-risk, fast-progressing course. In a retrospective cohort of 248 patients, 135 of whom had metastatic disease at presentation, tumors are classified as B7-H3 high when at least half of tumor cells show moderate-to-strong membranous staining. High B7-H3 correlates with higher PSA and more aggressive disease, and it predicts worse overall and cancer-specific survival even after adjusting for PSA, Gleason grade, age, and metastatic spread, with a reported hazard ratio greater than 2. If correct, this would give clinicians a biomarker available at diagnosis for early risk stratification and for selecting patients for B7-H3-targeted therapies. It also extends earlier B7-H3 findings from prostatectomy and localized disease to treatment-naive metastatic biopsies.","feed_headline":"B7-H3 in first biopsy flags high-risk metastatic prostate cancer","feed_subtitle":"In 248 men, high tumor B7-H3 at diagnosis tracked worse survival even after adjusting for PSA and Gleason grade.","key_machinery":"The load-bearing measurement is B7-H3/CD276 membranous expression in archived treatment-naive needle biopsies, detected by a standardized immunohistochemistry protocol and scored independently by two pathologists blinded to outcome. Tumors are dichotomized as B7-H3 high when 50% or more of tumor cells show moderate-to-strong membranous staining. That binary status is then carried through Kaplan-Meier and log-rank survival analysis and multivariable Weibull and Cox regression with multiple imputation for missing clinical values; the multivariable survival models are what establish the claim of independence from PSA, Gleason grade, age, and metastatic distribution.","core_discovery":"On the authors' own account, the central discovery is that high membranous B7-H3 expression in baseline diagnostic biopsies is an independent prognostic marker in metastatic prostate cancer. In the metastatic subset, 41 of 135 patients were classified as B7-H3 high. These patients had higher median PSA (130 vs 95 ng/mL) and a higher frequency of Gleason grade 5 tumors. Kaplan-Meier estimates showed five-year overall survival of about 40% in the high group versus 62% in the low group, and disease-specific survival of 64% versus 86%; the survival gap was already visible at one year. In multivariable Weibull and Cox models adjusted for age, PSA, Gleason grade, and visceral metastases, high B7-H","pith_inferences":["The paper leaves implicit a testable therapeutic prediction: if B7-H3 is an active driver rather than a correlate, biomarker-stratified trials randomizing high expressors to B7-H3 blockade should show a larger treatment effect in the high group; the current observational data cannot establish this.","The subgroup patterns, with a stronger effect in younger patients and in chemotherapy-treated patients, are hypothesis-generating rather than confirmatory given modest subgroup sizes; a prospective study with prespecified interaction tests and a uniform treatment protocol would be needed to make them actionable.","A natural extension would be to replace the 50% cutpoint with a continuous or algorithm-scored B7-H3 measure and compare discrimination against established tools; the paper reports no such head-to-head comparison."],"forward_implications":["High B7-H3 at baseline biopsy separates a group of metastatic prostate cancer patients with markedly shorter survival, including a roughly 20-point gap in five-year overall survival.","B7-H3 status could be added to standard risk assessment at diagnosis, because the survival association persists after adjustment for PSA, Gleason grade, age, and metastasis.","Trials of B7-H3-targeted therapies, such as antibody-drug conjugates or CAR-T cells, could use baseline B7-H3 expression to enrich for patients most likely to progress and potentially respond.","The early divergence in survival curves implies that high B7-H3 patients may warrant intensified monitoring or earlier treatment decisions from the time of diagnosis."],"supporting_citations":[{"why":"Prior study of B7-H3 in diagnostic biopsy specimens of metastatic prostate cancer; supplies the design template that this cohort and analysis repeat.","marker":"(Amori et al., 2021)"},{"why":"Established high B7-H3/B7x expression in human prostate cancer and its association with disease spread and poor outcome, the rationale for studying it in advanced disease.","marker":"(Zang et al., 2007)"},{"why":"Earlier evidence that B7-H3 is a prognostic marker and potential target in prostate cancer, including the caveat that scoring methods vary across studies.","marker":"(Roth et al., 2007)"},{"why":"Expression-based analysis linking B7-H3 to androgen receptor and immune pathways with poor outcome; supports B7-H3 as an independent prognostic signal.","marker":"(Benzon et al., 2017b)"},{"why":"Reviews PI3K/Akt and MAPK pathways downstream of B7-H3 and frames B7-H3 as an immunotherapy target, motivating the therapeutic implications.","marker":"(Picarda et al., 2016)"},{"why":"Associates B7-H3-expressing cells with proliferation, immune evasion, and earlier recurrence in localized prostate cancer; the localized-disease benchmark the metastatic results extend.","marker":"(Liu et al., 2012)"}],"fun_headline_variants":["B7-H3 at biopsy predicts worse prostate cancer survival","High B7-H3 in initial prostate biopsy signals poor outcome","B7-H3 expression in first biopsy marks aggressive prostate cancer","Baseline B7-H3 levels forecast survival in advanced prostate cancer","B7-H3 in diagnostic biopsy linked to shorter prostate cancer survival"],"cache_read_input_tokens":2816,"weakest_assumption_plain":"Everything rests on the rule that 'B7-H3 high' means at least half of tumor cells stain strongly; the authors themselves note that no consensus cutoff exists, and they neither optimize this threshold nor validate it in an external cohort.","fun_headline_variants_meta":{"raw":{"variants":["B7-H3 at biopsy predicts worse prostate cancer survival","High B7-H3 in initial prostate biopsy signals poor outcome","B7-H3 expression in first biopsy marks aggressive prostate cancer","Baseline B7-H3 levels forecast survival in advanced prostate cancer","B7-H3 in diagnostic biopsy linked to shorter prostate cancer survival"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000151,"raw_usage":{"total_tokens":1014,"prompt_tokens":702,"completion_tokens":312,"prompt_tokens_details":{"cached_tokens":256},"prompt_cache_hit_tokens":256,"prompt_cache_miss_tokens":446,"completion_tokens_details":{"reasoning_tokens":225}},"tokens_in":446,"tokens_out":312,"duration_ms":3589,"temperature":1.0,"reasoning_tokens":225,"cache_read_input_tokens":256,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-05T21:05:33.358747+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"Rescore the 135 metastatic biopsies with the percentage of stained tumor cells treated as a continuous variable or with cutpoints other than 50%, then test the chosen cutpoint in a separate treatment-naive metastatic cohort using the same antibody, scoring rules, and multivariable adjustment; the central claim fails if the hazard ratio for high versus low B7-H3 is no longer clearly above 1 or is not stable across plausible cutpoints.","supporting_citations":[{"cited_title":null,"cited_arxiv_id":null,"evidence_quote":"Prior study of B7-H3 in diagnostic biopsy specimens of metastatic prostate cancer; supplies the design template that this cohort and analysis repeat."},{"cited_title":"H., Al-Ahmadie, H","cited_arxiv_id":null,"evidence_quote":"Established high B7-H3/B7x expression in human prostate cancer and its association with disease spread and poor outcome, the rationale for studying it in advanced disease."},{"cited_title":"J., Sheinin, Y., Lohse, C","cited_arxiv_id":null,"evidence_quote":"Earlier evidence that B7-H3 is a prognostic marker and potential target in prostate cancer, including the caveat that scoring methods vary across studies."},{"cited_title":"C., and Zang, X","cited_arxiv_id":null,"evidence_quote":"Reviews PI3K/Akt and MAPK pathways downstream of B7-H3 and frames B7-H3 as an immunotherapy target, motivating the therapeutic implications."},{"cited_title":null,"cited_arxiv_id":null,"evidence_quote":"Associates B7-H3-expressing cells with proliferation, immune evasion, and earlier recurrence in localized prostate cancer; the localized-disease benchmark the metastatic results extend."}],"review_version":1}